TLIS
Talis Biomedical Corporation [TLIS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
TLIS Stock Summary
Top 10 Correlated ETFs
TLIS
Top 10 Correlated Stocks
TLIS
In the News
TLIS Financial details
Company Rating
Neutral
Market Cap
15.46M
Income
-60.84M
Revenue
412K
Book val./share
2.18
Cash/share
2.42
Dividend
-
Dividend %
-
Employees
99
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-1.14
Forward P/E
-
PEG
0.2
P/S
697.36
P/B
0.18
P/C
3.72
P/FCF
-4.58
Quick Ratio
10.41
Current Ratio
10.6
Debt / Equity
0.28
LT Debt / Equity
0.24
-
-
EPS (TTM)
-26.63
EPS next Y
-
EPS next Q
-
EPS this Y
-45.36%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
34.65%
Revenue last 5Y
-36.46%
Revenue Q/Q
98.68%
EPS Q/Q
-95.13%
-
-
-
-
SMA20
-4.28%
SMA50
11.26%
SMA100
23.19%
Inst Own
12.45%
Inst Trans
0.28%
ROA
-12%
ROE
-12%
ROC
-0.81%
Gross Margin
-543%
Oper. Margin
-21867%
Profit Margin
-3501%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.35-9.32
52W High
0%
52W Low
+125%
RSI
62.15
Rel Volume
0.91
Avg Volume
8.45K
Volume
7.69K
Perf Week
7.78%
Perf Month
9.09%
Perf Quarter
96.94%
Perf Half Y
67.29%
-
-
-
-
Beta
1.738
-
-
Volatility
0.18%, 0.37%
Prev Close
6.51%
Price
9
Change
5.26%
TLIS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.12 | 2.96 | 0 | 2.06 | 0.23 | |
| Net income per share | -7.71 | -24.61 | -50.77 | -62.45 | -34.12 | |
| Operating cash flow per share | -6.84 | -23.52 | -45.68 | -56.4 | -29.29 | |
| Free cash flow per share | -7 | -25.74 | -46.45 | -57.31 | -29.56 | |
| Cash per share | 6.07 | 37.43 | 61.99 | 73.32 | 42.22 | |
| Book value per share | -5.94 | -29.34 | 62.37 | 71.38 | 38.03 | |
| Tangible book value per share | -5.94 | -29.34 | 62.37 | 71.38 | 38.03 | |
| Share holders equity per share | -5.94 | -29.34 | 62.37 | 71.38 | 38.03 | |
| Interest debt per share | -0.07 | 0.19 | 3.73 | 17.72 | 10.82 | |
| Market cap | 1.48B | 1.54B | 225.65M | 11.88M | 13.54M | |
| Enterprise value | 1.46B | 1.41B | 7.08M | -84.73M | -43.52M | |
| P/E ratio | -54.06 | -16.94 | -1.18 | -0.11 | -0.22 | |
| Price to sales ratio | 372.88 | 141.06 | 0 | 3.25 | 32.87 | |
| POCF ratio | -60.96 | -17.73 | -1.32 | -0.12 | -0.25 | |
| PFCF ratio | -59.55 | -16.2 | -1.29 | -0.12 | -0.25 | |
| P/B Ratio | -70.15 | -14.21 | 0.96 | 0.09 | 0.2 | |
| PTB ratio | -70.15 | -14.21 | 0.96 | 0.09 | 0.2 | |
| EV to sales | 367.45 | 128.46 | 0 | -23.2 | -105.64 | |
| Enterprise value over EBITDA | -56.26 | -15.54 | -0.04 | 0.74 | 0.72 | |
| EV to operating cash flow | -60.07 | -16.15 | -0.04 | 0.85 | 0.82 | |
| EV to free cash flow | -58.68 | -14.76 | -0.04 | 0.83 | 0.81 | |
| Earnings yield | -0.02 | -0.06 | -0.84 | -9.33 | -4.58 | |
| Free cash flow yield | -0.02 | -0.06 | -0.77 | -8.57 | -3.97 | |
| Debt to equity | 0.01 | -0.01 | 0.06 | 0.26 | 0.28 | |
| Debt to assets | -0.01 | 0 | 0.05 | 0.2 | 0.2 | |
| Net debt to EBITDA | 0.83 | 1.52 | 1.14 | 0.84 | 0.94 | |
| Current ratio | 5.97 | 11.78 | 12.36 | 10.52 | 8.86 | |
| Interest coverage | 0 | 0 | 0 | 54.13 | 0 | |
| Income quality | 0.89 | 0.95 | 0.89 | 0.89 | 0.86 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.73 | 1.2 | 0 | 0 | 0 | |
| Research and developement to revenue | 5.99 | 8.14 | 0 | 19.4 | 98.77 | |
| Intangibles to total assets | 0 | 0 | 0 | -0.05 | -0.02 | |
| Capex to operating cash flow | 0.02 | 0.09 | 0.02 | 0.02 | 0.01 | |
| Capex to revenue | -0.15 | -0.75 | 0 | -0.44 | -1.18 | |
| Capex to depreciation | -0.8 | -10.75 | -1.82 | -0.18 | -0.1 | |
| Stock based compensation to revenue | 0.24 | 0.34 | 0 | 1.47 | 10.56 | |
| Graham number | 32.12 | 127.48 | 266.92 | 316.7 | 170.85 | |
| ROIC | 1.25 | 0.85 | -0.73 | -0.58 | -0.62 | |
| Return on tangible assets | -1.07 | -0.46 | -0.72 | -0.62 | -0.62 | |
| Graham Net | -6.72 | -39.14 | 53.53 | 49.49 | 26.16 | |
| Working capital | 20.07M | 172.7M | 217.01M | 120.61M | 68.91M | |
| Tangible asset value | -21.14M | -108.57M | 233.98M | 135.98M | 70.66M | |
| Net current asset value | -22.77M | -118.25M | 204.26M | 90.73M | 48.46M | |
| Invested capital | 0.01 | -0.01 | 0.06 | 0.26 | 0.28 | |
| Average receivables | 1.9M | 1.14M | 327K | 245.5K | 179K | |
| Average payables | 1.54M | 3.24M | 5.01M | 4.45M | 2.55M | |
| Average inventory | 0 | 23.33M | 23.33M | 0 | 0 | |
| Days sales outstanding | 165.75 | 15.72 | 0 | 30.78 | 44.3 | |
| Days payables outstanding | 0 | 0 | 713.29 | 163.9 | 95.55 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 2.2 | 23.22 | 0 | 11.86 | 8.24 | |
| Payables turnover | 0 | 0 | 0.51 | 2.23 | 3.82 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 1.3 | 0.84 | -0.81 | -0.87 | -0.9 | |
| Capex per share | -0.16 | -2.22 | -0.76 | -0.91 | -0.27 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.06 | 0.08 | 0.03 | 0.04 | 0 | |
| Net income per share | 19.31 | -9.32 | -8.27 | -8.62 | -0.42 | |
| Operating cash flow per share | -7.58 | -9.21 | -7.85 | -6.13 | -0.36 | |
| Free cash flow per share | -7.61 | -9.22 | -8.12 | -6.16 | -0.36 | |
| Cash per share | 72.88 | 63.19 | 54.04 | 48.37 | 2.42 | |
| Book value per share | 70.95 | 61.6 | 52.92 | 44.83 | 2.18 | |
| Tangible book value per share | 70.95 | 61.6 | 52.92 | 44.83 | 2.18 | |
| Share holders equity per share | 70.95 | 61.6 | 52.92 | 44.83 | 2.18 | |
| Interest debt per share | -15.59 | 7.58 | 11.22 | 11.04 | 0.62 | |
| Market cap | 11.95M | 13.14M | 13.08M | 10.5M | 236.06M | |
| Enterprise value | -84.66M | -85.11M | -64.73M | -57.42M | 178.99M | |
| P/E ratio | 0.09 | -0.2 | -0.22 | -0.17 | -4.38 | |
| Price to sales ratio | 111.69 | 95.91 | 272.59 | 138.11 | 1.56K | |
| POCF ratio | -0.88 | -0.8 | -0.92 | -0.94 | -20.79 | |
| PFCF ratio | -0.88 | -0.8 | -0.89 | -0.94 | -20.96 | |
| P/B Ratio | 0.09 | 0.12 | 0.14 | 0.13 | 3.42 | |
| PTB ratio | 0.09 | 0.12 | 0.14 | 0.13 | 3.42 | |
| EV to sales | -791.2 | -621.23 | -1.35K | -755.49 | 1.19K | |
| Enterprise value over EBITDA | 3.01 | 4.52 | 3.99 | 3.43 | -12.89 | |
| EV to operating cash flow | 6.25 | 5.17 | 4.53 | 5.15 | -15.76 | |
| EV to free cash flow | 6.23 | 5.16 | 4.39 | 5.12 | -15.89 | |
| Earnings yield | 2.89 | -1.27 | -1.15 | -1.49 | -0.06 | |
| Free cash flow yield | -1.14 | -1.25 | -1.13 | -1.07 | -0.05 | |
| Debt to equity | 0.26 | 0.13 | 0.21 | 0.25 | 0.28 | |
| Debt to assets | 0.2 | 0.11 | 0.17 | 0.19 | 0.2 | |
| Net debt to EBITDA | 3.44 | 5.22 | 4.8 | 4.05 | 4.11 | |
| Current ratio | 10.52 | 10.34 | 11.01 | 10.6 | 8.86 | |
| Interest coverage | 0.46 | 16.29 | 0 | 0 | 0 | |
| Income quality | 0.5 | 0.92 | 0.95 | 0.71 | 0.84 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 142.45 | 100.7 | 219.9 | 109.24 | 53.25 | |
| Intangibles to total assets | -0.05 | 0 | 0 | 0 | -0.02 | |
| Capex to operating cash flow | 0 | 0 | 0.03 | 0.01 | -0.01 | |
| Capex to revenue | -0.46 | -0.18 | -10.1 | -0.92 | 0.62 | |
| Capex to depreciation | -0.01 | -0.14 | -2.89 | -0.32 | 0.15 | |
| Stock based compensation to revenue | 11.98 | 8.64 | 22.42 | 14.11 | 6.75 | |
| Graham number | 175.57 | 113.67 | 99.25 | 93.25 | 4.57 | |
| ROIC | 0.19 | -0.13 | -0.12 | -0.14 | -0.14 | |
| Return on tangible assets | 0.19 | -0.13 | -0.12 | -0.15 | -0.13 | |
| Graham Net | 49.19 | 50.7 | 39.73 | 34.26 | 1.5 | |
| Working capital | 120.61M | 104.41M | 92.7M | 81.08M | 68.91M | |
| Tangible asset value | 135.98M | 110.12M | 96.17M | 81.56M | 70.66M | |
| Net current asset value | 90.73M | 92.66M | 75.06M | 63.86M | 48.46M | |
| Invested capital | 0.26 | 0.13 | 0.21 | 0.25 | 0.28 | |
| Average receivables | 370.5K | 217.5K | 329.5K | 268.5K | 27.5K | |
| Average payables | 3.94M | 3.82M | 3.18M | 2.59M | 2.02M | |
| Average inventory | 1.01M | 505K | 1.01M | 505K | 0 | |
| Days sales outstanding | 259.07 | 83.43 | 997.5 | 5.92 | 29.8 | |
| Days payables outstanding | 145.42 | 17.42K | 32.03K | 40.46K | 193.75 | |
| Days of inventory on hand | 0 | 4.55K | 12.99K | 0 | 0 | |
| Receivables turnover | 0.35 | 1.08 | 0.09 | 15.2 | 3.02 | |
| Payables turnover | 0.62 | 0.01 | 0 | 0 | 0.46 | |
| Inventory turnover | 0 | 0.02 | 0.01 | 0 | 0 | |
| ROE | 0.27 | -0.15 | -0.16 | -0.19 | -0.19 | |
| Capex per share | -0.03 | -0.01 | -0.27 | -0.04 | 0 |
TLIS Frequently Asked Questions
What is Talis Biomedical Corporation stock symbol ?
Talis Biomedical Corporation is a US stock , located in Menlo park of Ca and trading under the symbol TLIS
What is Talis Biomedical Corporation stock quote today ?
Talis Biomedical Corporation stock price is $9 today.
Is Talis Biomedical Corporation stock public?
Yes, Talis Biomedical Corporation is a publicly traded company.
Company Profile
- Volume Average 8.45K
- Market Capitalization 15.46M
- Employee 99
- CEO Mr. Robert Kelley MBA
- Headquarters Menlo Park,CA,US
- IPO Date 2021-02-12
-
Website
https://talisbio.com 
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
